Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
24.07.2026 13:10
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
Par Health Launches First and Only Generic Version of Janumet® XR (sitagliptin and metformin HCl extended-release) Tablets in the United States
24.07.2026 12:00
Par Health, Inc. ("Par Health" or the "Company"), a global pharmaceutical company and manufacturer of essential medicines, today announced the launch of its generic version of Merck's Janumet® XR (sitagliptin and metformin HCl extended-release) tablets for oral use, following final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application.
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
24.07.2026 10:45
RAHWAY, N.J., July 24, 2026--Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally.
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026
22.07.2026 04:28
Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
21.07.2026 10:00
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, has expanded their clinical trial collaboration with Merck (known as MSD outside of the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy in 1L BTC.
Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug
19.07.2026 13:06
Merck (NYSE:MRK) received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable PCSK9 therapies. The approval expands Merck’s presence in cardiovascular medicine as key products approach patent expirations. Merck, trading around $127.5, is adding Lipfendra to its portfolio at a time when NYSE:MRK has posted a 64.8% return over the past year and 92.2% over five years. The...
Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says
16.07.2026 15:40
Merck (MRK) is approaching key pipeline catalysts with ISLEND and islatravir plus ulonivirine data t
Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
16.07.2026 15:39
Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.
Dow Jones' Merck Snags A First-Of-Its-Kind Approval, And Jumps
16.07.2026 13:12
Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.
Merck Opens BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
16.07.2026 12:20
Merck Opens BioReliance® Testing Facility in Darmstadt, Germany The facility expands access to commercial drug substance and drug product release testing as well as stability testing for biopharmaceutical companies developing and commercializing therapies in Europe. Darmstadt, Germany, July 16, 2026 (GLOBE NEWSWIRE) -- New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing and GMP-compliant stability studiesStrategic
Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
16.07.2026 12:17
It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
16.07.2026 10:45
RAHWAY, N.J., July 16, 2026--Merck’s LIPFENDRA is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Merck Gets Approval for Powerful Cholesterol-Cutting Pill
16.07.2026 10:45
It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
Merck wins first approval of a PCSK9 cholesterol pill
16.07.2026 09:22
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.
Merck Says FDA Approves LIPFENDRA Tablets 20 Mg As Adjunct To Diet And Exercise To Reduce Low-Density Lipoprotein Cholesterol In Adults With Hypercholesterolemia
16.07.2026 06:46
At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectivelyLIPFENDRA is a novel macrocyclic peptide that binds to PCSK9 and
SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up
14.07.2026 15:06
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. Read more on SLS stock here.
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
14.07.2026 13:53
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
Earnings Preview: What To Expect From Merck & Co.'s Report
14.07.2026 12:10
Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.
Merck (MRK) Stock Looks Like A Bargain At This Price
13.07.2026 13:09
Merck stock has delivered an 87.4% return over the past 5 years. The current Discounted Cash Flow (DCF) estimate now points to meaningful upside relative to the US$123.54 share price, while the broader valuation checks paint a more mixed picture. Over 5 years, Merck has returned 87.4%. This puts current buyers in the position of judging whether that past compounding already reflects much of the company’s progress. Ongoing expansion of the Keytruda and broader oncology pipeline may support...
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
13.07.2026 12:00
INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation profile compared with previous studies TACTI-004 root cause analysis is ongoing with additional results expected in Q3 CY2026 SYDNEY, AUSTRALIA, July 13, 2026